HELSINKI, FINLAND--(Marketwire - October 30, 2008) - Finnish biotechnology company Mobidiag launches its first CE-marked product for In Vitro Diagnostics (IVD) of sepsis. The microarray-based Prove-it™ Sepsis is invincible in both the coverage and the rate of detecting dangerous bacteria including the superbug MRSA from positive blood culture samples in a single test. The test enables simultaneous identification of 50 species in less than three hours. Based on the excellent performance of 3300 patient samples in the University College London Hospitals and the Hospital Districts of Helsinki and Uusimaa (HUS, Finland) the assay is now qualified for reliable clinical diagnostics.
